Can you take Chlorotrianisene with Semaglutide?
1 drug interaction and 9 additional warnings found for the following 2 drugs:
- chlorotrianisene
- semaglutide
Drug interactions
Moderate drug interactions
Moderate:
chlorotrianisene semaglutide
Applies to: chlorotrianisene and semaglutide
Chlorotrianisene may interfere with blood glucose control and reduce the effectiveness of semaglutide and other diabetic medications. Monitor your blood sugar levels closely. You may need a dose adjustment of your diabetic medications during and after treatment with chlorotrianisene. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
semaglutide Food/Lifestyle
Applies to: semaglutide
Food may affect the absorption of semaglutide when taken orally. It is recommended that oral semaglutide be taken 30 minutes before first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water. You may experience more side effects including nausea, vomiting, and diarrhea if you fast longer than 30 minutes after the semaglutide dose. Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Minor food/lifestyle interactions
Minor:
chlorotrianisene Food/Lifestyle
Applies to: chlorotrianisene
Information for this minor interaction is available on the professional version.
Disease interactions
7 potential interactions Applies to: 7 conditions, including Diarrhea, Gastroparesis, Dehydration, Diabetic Retinopathy, and Thyroid Tumor.
Dehydration
Moderate:
semaglutide
Semaglutide has a moderate potential interaction with Dehydration.
There have been postmarketing reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with semaglutide. The majority of events occurred in patients with gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea); therefore, semaglutide is not recommended in patients with severe gastroparesis. It is recommended to monitor renal function in patients reporting adverse reactions to semaglutide that may lead to volume depletion, especially when initiating or escalating doses of semaglutide.
Diabetic Retinopathy
Moderate:
semaglutide
Semaglutide has a moderate potential interaction with Diabetic Retinopathy.
Patients with history of diabetic retinopathy should be monitored for progression of diabetic retinopathy during treatment with semaglutide. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.
Diarrhea
Moderate:
semaglutide
Semaglutide has a moderate potential interaction with Diarrhea.
There have been postmarketing reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with semaglutide. The majority of events occurred in patients with gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea); therefore, semaglutide is not recommended in patients with severe gastroparesis. It is recommended to monitor renal function in patients reporting adverse reactions to semaglutide that may lead to volume depletion, especially when initiating or escalating doses of semaglutide.
Gastroparesis
Moderate:
semaglutide
Semaglutide has a moderate potential interaction with Gastroparesis.
There have been postmarketing reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with semaglutide. The majority of events occurred in patients with gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea); therefore, semaglutide is not recommended in patients with severe gastroparesis. It is recommended to monitor renal function in patients reporting adverse reactions to semaglutide that may lead to volume depletion, especially when initiating or escalating doses of semaglutide.
Multiple Endocrine Neoplasia Type II
Major:
semaglutide
Semaglutide has a major potential interaction with Multiple Endocrine Neoplasia Type II.
The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. It is recommended to counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.
Thyroid Tumor
Major:
semaglutide
Semaglutide has a major potential interaction with Thyroid Tumor.
The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. It is recommended to counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.
Vomiting
Moderate:
semaglutide
Semaglutide has a moderate potential interaction with Vomiting.
There have been postmarketing reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with semaglutide. The majority of events occurred in patients with gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea); therefore, semaglutide is not recommended in patients with severe gastroparesis. It is recommended to monitor renal function in patients reporting adverse reactions to semaglutide that may lead to volume depletion, especially when initiating or escalating doses of semaglutide.
Report options
More resources
chlorotrianisene
A total of 260 drugs are known to interact with chlorotrianisene.
- Chlorotrianisene is in the drug class estrogens.
- Chlorotrianisene is used to treat Postmenopausal Symptoms.
semaglutide
A total of 404 drugs are known to interact with semaglutide.
- Semaglutide is in the drug class GLP-1 Drugs.
- Semaglutide is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.